Combining EGFR and MET Inhibition With Crizotinib in EGFR-mutated Lung Adenocarcinoma Harboring MET Amplification: A Brief Report

Clin Lung Cancer. 2020 Nov;21(6):e601-e606. doi: 10.1016/j.cllc.2020.05.015. Epub 2020 May 23.
No abstract available

Keywords: Combination targeted therapies; EGFR TKI; Lung cancer; MET amplification; Resistance.

Publication types

  • Case Reports

MeSH terms

  • Acrylamides / administration & dosage
  • Adenocarcinoma of Lung / genetics
  • Adenocarcinoma of Lung / pathology
  • Adenocarcinoma of Lung / therapy*
  • Adult
  • Aged
  • Aniline Compounds / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Brain Neoplasms / genetics
  • Brain Neoplasms / secondary
  • Brain Neoplasms / therapy*
  • Crizotinib / administration & dosage
  • ErbB Receptors / antagonists & inhibitors
  • ErbB Receptors / genetics
  • Female
  • Humans
  • Lung Neoplasms / genetics
  • Lung Neoplasms / pathology
  • Lung Neoplasms / therapy*
  • Male
  • Middle Aged
  • Mutation*
  • Prognosis
  • Proto-Oncogene Proteins c-met / antagonists & inhibitors*

Substances

  • Acrylamides
  • Aniline Compounds
  • osimertinib
  • Crizotinib
  • EGFR protein, human
  • ErbB Receptors
  • MET protein, human
  • Proto-Oncogene Proteins c-met